摘要
目的:观察质子泵抑制剂联合复方消化酶片治疗伴腹胀的上腹痛综合征型功能性消化不良的疗效和安全性。方法:156例伴腹胀的上腹痛综合征型功能性消化不良患者随机分为对照组(75例)和观察组(81例)。对照组患者给予埃索美拉唑肠溶片40 mg,每日早餐前半小时服用1次;观察组患者在对照组治疗的基础上加用复方消化酶片243.6 mg,每日3次,餐后即服。两组疗程均为2周。观察两组患者的临床疗效,治疗前后临床症状评分和胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PGⅡ)水平,餐后2、4 h胃排空率及不良反应发生情况。结果:观察组患者总有效率显著高于对照组,差异有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。治疗前,两组患者临床症状评分和PGⅠ、PGⅡ水平,餐后2、4 h胃排空率比较,差异均无统计学意义(P>0.05)。治疗后,两组患者临床症状评分均显著低于同组治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05);观察组患者PGⅠ、PGⅡ水平均显著高于同组治疗前及对照组,差异均有统计学意义(P<0.05);两组患者治疗前后餐后2、4 h胃排空率及对照组患者PGⅠ、PGⅡ水平比较,差异均无统计学意义(P>0.05)。结论 :质子泵抑制剂联合复方消化酶片治疗伴腹胀的上腹痛综合征型功能性消化不良的疗效显著优于单用质子泵抑制剂,且安全性相当。
OBJECTIVE： To observe the efficacy and safety of proton pump inhibitors combined with Compound digestive en- zyme tablet in the treatment of epigastrie pain syndrome with abdominal distension. METHODS： 156 patients with epigastric pain syndrome with abdominal distension were randomly divided into control group （75 cases） and observation group （81 cases）. Con- trol group was given 40 mg Esomeprazole enteric-coated tablet for once half an hour before breakfast; observation group was addi- tionally given 243.6 mg Compound digestive enzyme tablet immediately after meal, 3 times a day. The treatment course for both groups was 2 weeks. Clinical efficacy, clinical symptom score, pepsinogen I （PG I ）, pepsinogen Ⅱ （PG Ⅱ ）, 2,4 h postprandial gastric emptying rate before and after treatment, and incidence of adverse reactions in 2 groups were observed. RESULTS： The to- tal effective rate in observation group was significantly higher than control group, the difference was statistically significant （P〈 0.05）. There was no significant difference in the incidence of adverse reactions between 2 groups （P〉0.05）. Before treatment, there were no significant differences in the clinical symptom score, PG I , PGⅡ and 2, 4 h postprandial gastric emptying rate （P〉 0.05）. After treatment, clinical symptom score in 2 groups were significantly lower than before, and observation group was lower than control group; PG I and PG Ⅱ in observation group were significantly higher than before and control group, the differences were statistically significant（P〈0.05） ; and there were no significant differences in the 2, 4 h postprandial gastric emptying rate be- tween 2 groups and PG I and PG Ⅱ in control group before and after treatment （P〉0.05）. CONCLUSIONS： The efficacy of pro- ton pump inhibitors combined with Compound digestive enzyme tablet is superior to the proton pump inhibitors in the treatment of epigastric pain syndrome with abdominal distension, with similar safety.
出处
《中国药房》
CAS
北大核心
2016年第12期1608-1610,共3页
China Pharmacy
关键词
功能性消化不良
复方消化酶片
质子泵抑制剂
疗效
安全性
Functional dyspepsia
Compound digestive enzyme tablets
Proton pump inhibitors
Efficacy
Safety
